Premium
Intravitreal bevacizumab monotherapy for retinopathy of prematurity
Author(s) -
Şahin Alparslan,
Şahin Muhammed,
Cingü Abdullah Kürşat,
Çınar Yasin,
Türkcü Fatih Mehmet,
Yüksel Harun,
Kaya Savaş,
Arı Şeyhmus,
Çaça İhsan
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12124
Subject(s) - medicine , retinopathy of prematurity , bevacizumab , gestational age , ophthalmology , stage (stratigraphy) , retinal , retrospective cohort study , surgery , chemotherapy , pregnancy , paleontology , genetics , biology
Background The aim of this study was to evaluate the treatment outcomes of intravitreal bevacizumab ( IVB ) injections, used as a monotherapy in type 1 retinopathy of prematurity ( ROP ). Methods A retrospective chart review was performed for 17 type 1 ROP patients (34 eyes), who had IVB injection between J uly 2011 and J une 2012. Birthweight, gestational age at birth, stage and location of ROP , IVB injection time, time of complete retinal vascularization, and additional treatments if needed, were noted. A total of 0.625 mg (0.025 mL) bevacizumab was injected intravitreally. Results Thirty eyes of 17 patients with type 1 ROP enrolled in the study were treated with IVB injection. Of them seven had aggressive posterior‐ ROP , six had stage 2 ROP , and four had stage 3 ROP . The mean gestational age was 28.44 weeks (range, 26–31 weeks); and the mean birthweight was 1151.88 g (range, 600–1600 g). The mean age for IVB injection was 35.47 weeks. The mean full retinal vascularization time was 136.6 ± 26.6 days. The mean follow‐up time was 285.3 ± 70 days. ROP was regressed and retinal vascularization was completed in all cases except one eye, which had threshold disease. Conclusion IVB injection, used as a monotherapy, is an effective treatment approach in patients with type 1 ROP . Timely treatment of stage 2 and early stage 3 ROP in which disease progression was observed, prevents vitreoretinal membrane formation in posterior disease. Further studies need to be performed to determine the safety of IVB injection.